Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy

Social Author Image

https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg

Tweet Author

Social Author Name

Dr. John Cush

Tweet Content

Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9

Show on Archive Page

On

Display in Search Results

On

PDQ

Off

Topics

Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy

Do you get our email newsletter?